PubMed Health⌕ Search

PubMed · 1898509

Pathologic assessment of bone.

Abstract

Bone biopsy is an established diagnostic and investigative procedure that allows direct visualization of bone cells and structure and provides an indirect measure of bone turnover. It is widely used in management of metabolic bone disease and to explain any unclear biochemical abnormality affecting bone metabolism; it should become more widely used as its availability increases. Bone biopsy defines a variety of mineralization defects caused by fluoride, diphosphonates, and aluminum, and it provides unique insight into bone loss with age and with osteoporosis. It is necessary for evaluating rapidly progressive osteoporosis and it can be particularly useful for differentiating osteoporosis from osteomalacia. Although osteomalacia is often the result of decreased dietary vitamin D, there are recognized risk factors, such as previous gastric surgery or chronic renal disease. Nonetheless, clinical findings in osteomalacia are often rather subtle, and there may be few biochemical findings. Hence, if the patient is an elderly woman, and therefore also at risk for osteoporosis, the distinction can be difficult. Imaging studies are not likely to be helpful, since both disorders lead to decreased bone mass, usually at the same sites. The diagnostic criteria for osteomalacia are increased extent of osteoid surfaces, increased osteoid thickness, and thickened osteoid seams, in conjunction with a decreased calcification rate (as calculated by tetracycline labeling) and decreased calcification fronts. Osteoid volume alone is not an adequate diagnostic criterion, because it may also be increased in Paget's disease and hyperparathyroidism. Finally, biopsy is a valuable means to assess the effect of potential therapeutic agents on bone and bone cells.(ABSTRACT TRUNCATED AT 250 WORDS)

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

T B Aufdemorte. 1991. Pathologic assessment of bone.. https://doi.org/10.1080/21548331.1991.11704265

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Non-radical diagnostic biopsies do not negatively influence melanoma patient survival.

BACKGROUND: In fair-skinned Caucasian populations both the incidence and mortality rates of cutaneous melanoma have been increasing over the past decades. With adjuvant therapies still being under investigation, early detection is the only way to improve melanoma patient survival. The influence of incisional biopsies on melanoma patient survival has been discussed for many years. This study investigates both the influence of diagnostic biopsy type and the presence of residual tumor cells in the re-excision specimen on disease free and overall survival. METHODS: After (partial) removal of a pigmented skin lesion 471 patients were diagnosed with stage I/II melanoma and underwent re-excision and a sentinel node biopsy. All patients were followed prospectively, mean follow up >5 years. Patients were divided according to their diagnostic biopsy type (wide excision biopsy, narrow excision biopsy, excision biopsy with positive margins and incisional biopsy) and the presence of residual tumor cells in their re-excision specimen. Survival analysis was done using Cox's proportional hazard model adjusted for eight important confounders of melanoma patient survival. RESULTS: The diagnostic biopsy was wide in 279 patients, narrow in 109 patients, 52 patients underwent an excision biopsy with positive margins and 31 patients an incisional biopsy. In 41 patients residual tumor cells were present in the re-excision specimen. Both the diagnostic biopsy type and the presence of tumor cells in the re-excision specimen did not influence disease free and overall survival of melanoma patients. CONCLUSIONS: Non-radical diagnostic biopsies do not negatively influence melanoma patient survival.

Biopsy↗